Show simple item record

Authordc.contributor.authorSalas Huenuleo, Edison Sebastián
Authordc.contributor.authorHernández Jorquera, Andrea Carolina
Authordc.contributor.authorLobos González, Lorena
Authordc.contributor.authorPolakovicová, Iva
Authordc.contributor.authorMorales Zavala, Francisco Andrés
Authordc.contributor.authorAraya, Eyleen
Authordc.contributor.authorCelis, Freddy
Authordc.contributor.authorRomero Osses, Carmen Aurora
Authordc.contributor.authorKogan, Marcelo Javier
Admission datedc.date.accessioned2023-11-21T14:27:30Z
Available datedc.date.available2023-11-21T14:27:30Z
Publication datedc.date.issued2022
Cita de ítemdc.identifier.citationPharmaceutics 2022, 14, 958es_ES
Identifierdc.identifier.other10.3390/pharmaceutics14050958
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/196450
Abstractdc.description.abstractOne of the recent attractive therapeutic approaches for cancer treatment is restoring downregulated microRNAs. They play an essential muti-regulatory role in cellular processes such as proliferation, differentiation, survival, apoptosis, cell cycle, angiogenesis, and metastasis, among others. In this study, a gold nanoplatform (GNPF) carrying miR-145, a downregulated microRNA in many cancer types, including epithelial ovarian cancer, was designed and synthesized. For targeting purposes, the GNPF was functionalized with the FSH33 peptide, which provided selectivity for ovarian cancer, and loaded with the miR-145 to obtain the nanosystem GNPF-miR-145. The GNPF-mir-145 was selectively incorporated in A2780 and SKOV3 cells and significantly inhibited cell viability and migration and exhibited proliferative and anchor-independent growth capacities. Moreover, it diminished VEGF release and reduced the spheroid size of ovarian cancer through the damage of cell membranes, thus decreasing cell viability and possibly activating apoptosis. These results provide important advances in developing miR-based therapies using nanoparticles as selective vectors and provide approaches for in vivo evaluation.es_ES
Patrocinadordc.description.sponsorshipComision Nacional de Investigacion Cientifica y Tecnologica (CONICYT) CONICYT FONDECYT 1160139 3190547 1190623 1211482 PAI 77200057 Fondap 15130011es_ES
Lenguagedc.language.isoenes_ES
Publisherdc.publisherMDPIes_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
Sourcedc.sourcePharmaceuticses_ES
Keywordsdc.subjectOvarian canceres_ES
Keywordsdc.subjectNanoplatformes_ES
Keywordsdc.subjectMicroRNAes_ES
Títulodc.titlePeptide targeted gold nanoplatform carrying miR-145 induces antitumoral effects in ovarian cancer cellses_ES
Document typedc.typeArtículo de revistaes_ES
dc.description.versiondc.description.versionVersión publicada - versión final del editores_ES
dcterms.accessRightsdcterms.accessRightsAcceso abiertoes_ES
Catalogueruchile.catalogadorapces_ES
Indexationuchile.indexArtículo de publícación WoSes_ES


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States